An observational study in Acute Kidney Injury Due to Sepsis, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Seoul National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Acute Kidney Injury by Seoul National University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Acute Kidney Injury · Seoul National University Hospital.
Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, this one is the only one that started in 2024, is one of 7 observational ones, and was the 14th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →3 of the 18 studies in Acute Kidney Injury by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages up to 7
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is below the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 190 across the 11 interventional studies, 1,099 across the 7 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
1 of the studies in Acute Kidney Injury by Seoul National University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898944Seoul National University HospitalPrognosis and Risk Factors for Acute Kidney Injury | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in patients with severe acute kidney injury or sepsis, compared with standard membranes. Based on this benefit, the use of oXiris may confer better outcomes than other membranes.
The patient outcomes include cardiovascular, respiratory, renal, and overall survivals, but this information of oXiris are insufficient. Although cytokine and endotoxin removal rates are great in oXiris, the beneficial effects on the hard outcomes are needed to use oXiris in real clinical practice.
The inflammatory and cardiovascular systems have intensive crosstalk, and thus if there are remission in inflammatory process, the patients can have hemodynamic stability. Regarding this, the investigators would like to compare the hemodynamic stability between oXiris and other standard membrane such as polysulfone, using our new real-time monitoring registry.
Adult patients who have severe acute kidney injury and require continuous renal replacement therapy because of hemodynamic instability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with septic acute kidney injury requiring continuous renal replacement therapy
Device: oXiris membrane · Device: Polysulfone membrane
Perform continuous renal replacement therapy with oXiris membrane
Perform continuous renal replacement therapy with polysulfone membrane
Rate of all-cause mortality
Risk of all-cause mortality
Time frame: 28 days
Occurrence rates of ventricular tachycardia, intradialytic hypotension
Risk of ventricular tachycardia, intradialytic hypotension
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Dec 2025, 23 months.
Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 23 months is close to that.
Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jun 2026 → Dec 2025 and completion Dec 2026 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →